Kamada (KMDA) Cash from Financing Activities (2013 - 2026)
Kamada's (KMDA) quarterly Cash from Financing Activities came in at -$856000.0 in Q1 2026, down 192.15% YoY from $928918.5 in Q1 2025, and up 27.4% on a QoQ basis from -$1.2 million in Q4 2025.
Kamada (KMDA) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Kamada (KMDA) has 14 years of Cash from Financing Activities data on file, last reported at -$856000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 192.15% year-over-year to -$856000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$18.9 million (down 123.37% YoY) and the FY2025 annual result came in at -$18.3 million, down 31.87% from the prior year.
- Cash from Financing Activities rose to -$856000.0 in Q1 2026, from -$1.2 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $31.3 million in Q3 2023 to a low of -$16.1 million in Q2 2025.
- A 5-year average of -$961184.8 and a median of -$1.6 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 1384222.07% — and 2024, when it tumbled 199101.67%.
- Tracing KMDA's Cash from Financing Activities over 5 years: stood at -$2.9 million in 2022, then surged by 44.93% to -$1.6 million in 2023, then surged by 55.22% to -$708000.0 in 2024, then sank by 66.53% to -$1.2 million in 2025, then climbed by 27.4% to -$856000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$856000.0 (Q1 2026), -$1.2 million (Q4 2025), and -$754000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Kamada | 457.71 Mn | 428.24 Mn | 22.47 Mn | -19.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.00 Mn |
| Jun 30, 2026 | -19.00 Mn |
| Mar 31, 2026 | -856,000.00 |
| Mar 31, 2026 | -856,000.00 |
| Dec 31, 2025 | -1.18 Mn |
| Dec 31, 2025 | -1.18 Mn |
| Sep 30, 2025 | -754,000.00 |
| Sep 30, 2025 | -754,000.00 |
| Jun 30, 2025 | -16.12 Mn |
| Jun 30, 2025 | -16.12 Mn |
| Mar 31, 2025 | -293,000.00 |
| Mar 31, 2025 | -293,000.00 |
| Dec 31, 2024 | -708,000.00 |
| Dec 31, 2024 | -708,000.00 |
| Sep 30, 2024 | -4.79 Mn |
| Sep 30, 2024 | -4.79 Mn |
| Jun 30, 2024 | -2.68 Mn |
| Jun 30, 2024 | -2.68 Mn |
| Mar 31, 2024 | -5.74 Mn |
| Mar 31, 2024 | -5.74 Mn |